Viral vectors: from virology to transgene expression

Bouard, David; Alazard-Dany, Nathalie; Cosset, François‐Loïc

doi:10.1038/bjp.2008.349

Cited by 312 publications

(219 citation statements)

References 137 publications

(130 reference statements)

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…Both viral and nonviral approaches have been explored for gene delivery in the past (2,3). Among the methods developed so far, the procedure of hydrodynamic gene delivery has received significant attention in recent years because of its simplicity, convenience, safety, and effectiveness for in vivo gene delivery (4,5).…”

Section: Introductionmentioning

confidence: 99%

Intracellular Gene Transfer in Rats by Tail Vein Injection of Plasmid DNA

Zhou

Kamimura

Zhang

et al. 2010

AAPS J

View full text Add to dashboard Cite

Abstract. In this study, we examined the effect of various factors on gene delivery efficiency of tail vein injection of plasmid DNA into rats. We measured the level of reporter gene expression in the internal organs including the lung, heart, spleen, kidney, and liver as function of injection volume, injection time, and DNA dose. Persistency of reporter gene expression in transfected animals was also examined. We demonstrated that plasmid delivery to rats by the tail vein is effective as long as the volume of injected DNA solution is adjusted to 7-8% of body weight with an injection time of less than 10 s. With the exception of a short-term increase in serum concentration of alanine aminotransferase and transient irregularity in cardiac function during and soon after the injection, the procedure is well tolerated. Lac Z staining of the liver from transfected animals showed approximately 5-10% positive cells. Persistency test for transgene expression in animals using plasmid carrying cDNA of human alpha 1 antitrypsin gene driven by chicken beta actin gene promoter with CMV enhancers showed peak level of transgene product 1 day after the injection followed by a gradual decline with time. Peak level was regained by a second injection performed on day 38 after the first injection. These results show that tail vein injection is an effective means for introducing plasmid DNA into liver cells in rats. We believe that this procedure will be extremely useful for gene function studies in the context of whole animal in rats.

show abstract

Section: Introductionmentioning

confidence: 99%

Intracellular Gene Transfer in Rats by Tail Vein Injection of Plasmid DNA

Zhou

Kamimura

Zhang

et al. 2010

AAPS J

View full text Add to dashboard Cite

show abstract

“…Another strategy that may be interesting to consider regards the alteration of the viral envelope so that it becomes specific for a certain cell type: LVVs are usually pseudotyped with a VSV-G envelope, a glycoprotein that interacts with a ubiquitous receptor and that confers the viral particles a broad host-cell range. The tropism of LVVs may be controlled by using alternative glycoproteins that preferentially interact with specific cell types or by genetic modification of the viral surface (this topic has been reviewed by Bouard et al 70 ).…”

Section: Final Considerationsmentioning

confidence: 99%

Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function

et al. 2012

View full text Add to dashboard Cite

Engineered recombinant viral vectors are a powerful tool for vehiculating genetic information into mammalian cells. Because of their ability to infect both dividing and non-dividing cells with high efficiency, lentiviral vectors have gained particular interest for basic research and preclinical studies in the cardiovascular field. We review here the major applications for lentiviral-vector technology in the cardiovascular field: we will discuss their use in trailing gene expression during the induction of differentiation, in protocols for the isolation of cardiac cells and in the tracking of cardiac cells after transplantation in vivo; we will also describe lentivirally-mediated gene delivery uses, such as the induction of a phenotype of interest in a target cell or the treatment of cardiovascular diseases. In addition, a section of the review will be dedicated to reprogramming approaches, focusing attention on the generation of pluripotent stem cells and on transdifferentiation, two emerging strategies for the production of cardiac myocytes from human cells and for the investigation of human diseases. Finally, in order to give a perspective on their future clinical use we will critically discuss advantages and disadvantages of lentivirus-based strategies for the treatment of cardiovascular diseases.

show abstract

“…The viruses predominantly used for gene delivery include retroviruses, lentiviruses, adenoviruses and adeno-associated viruses. 9 In contrast, nonviral gene delivery can be achieved with physical methods, such as microinjection, gene gun, electroporation, impalefection, hydrostatic pressure, continuous infusion and sonication, or chemical methods such as lipofection. 10 Although nonviral delivery may have some advantages, the efficacy of this system is too low for clinical use.…”

Section: Introductionmentioning

confidence: 99%

Coxsackievirus B3 used as a gene therapy vector to express functional FGF2

Kim

et al. 2011

Gene Ther

View full text Add to dashboard Cite

Current gene therapies are predominantly based on a handful of viral vectors. The limited choice of delivery vectors has been one of the stumbling blocks to the advancement of gene therapy. Therefore, the development of novel recombinant vectors should facilitate the application of gene therapies. In this study, we examined coxsackievirus B3 (CVB3) as a novel recombinant vector for the delivery and expression of a foreign gene in vitro and in vivo. A recombinant CVB3 complementary DNA was constructed by inserting a gene encoding human fibroblast growth factor 2 (FGF2). The recombinant virus (CVB3 --FGF2) efficiently expressed FGF2 in HeLa cells and human cardiomyocytes in vitro and in mouse hindlimbs in vivo. The injection of the recombinant virus into mice with ischemic hindlimbs protected the hindlimbs from ischemic necrosis. CVB3 --FGF2 injection significantly improved the blood flow in the ischemic limbs for over 3 weeks compared with that in the phosphate-buffered saline-or CVB3-injected controls, suggesting that FGF2 expressed from CVB3 --FGF2 is functional and therapeutically effective. The virulence of CVB3 was also drastically attenuated in the recombinant virus. Thus, CVB3 can be modified to express a functional foreign protein, supporting its use as a novel viral vector for gene therapy.

show abstract

Viral vectors: from virology to transgene expression

Cited by 312 publications

References 137 publications

Intracellular Gene Transfer in Rats by Tail Vein Injection of Plasmid DNA

Intracellular Gene Transfer in Rats by Tail Vein Injection of Plasmid DNA

Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function

Coxsackievirus B3 used as a gene therapy vector to express functional FGF2

Contact Info

Product

Resources

About